Detection of tumours of the urinary tract in voided urine

Scandinavian Journal of Urology and Nephrology

Volumn 42, Issue SUPPL.218, 2008, Pages 147-153

  Zwarthoff, Ellen C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bladder; Detection; Recurrence; Screening; Urine

Indexed keywords

CYTOKERATIN 19 FRAGMENT; CYTOKERATIN 20; FAS LIGAND; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HYALURONIC ACID; HYALURONIDASE; NUCLEAR MATRIX PROTEIN 22; TUMOR MARKER;

CANCER DIAGNOSIS; CONFERENCE PAPER; CYSTOSCOPY; DISEASE MARKER; EARLY DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MASS SPECTROMETRY; MEDICAL LITERATURE; METHYLATION; MICROSATELLITE MARKER; MUTATION; PERFORMANCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINARY TRACT TUMOR; METHODOLOGY; REVIEW; TUMOR RECURRENCE; URINARY TRACT CANCER; URINE;

HUMANS; NEOPLASM RECURRENCE, LOCAL; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; UROLOGIC NEOPLASMS;

EID: 52949091586     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/03008880802283953     Document Type: Conference Paper

References (45)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Kiemeney LA, Witjes JA, Verbeek AL, Heijbroek RP, Debruyne FM. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer 1993;67:806-12.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-75.
4. van der Aa MN, Steyerberg EW, Sen EF, Zwarthoff EC, Kirkels WJ, van der Kwast TH, et al. Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. BJU Int 2008;101:1106-10.
5. Almallah YZ, Rennie CD, Stone J, Lancashire MJ. Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation. Urology 2000;56:37-9.
6. Wright MP, Jones DJ. Surveillance for bladder cancer: the management of 4.8 million people. South-west Urologists. BJU Int 2000;85:431-3.
7. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47:736-48.
8. Fernandez-Gomez J, Rodriguez-Martinez JJ, Barmadah SE, Garcia Rodriguez J, Allende DM, Jalon A, et al. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur Urol. 2007;51:1267-74.
9. Miyanaga N, Akaza H, Tsukamoto S, Shimazui T, Ohtani M, Ishikawa S, et al. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection. Int J Clin Oncol 2003;8:369-73.
10. Shariat SF, Casella R, Wians FH Jr, Ashfaq R, Balko J, Sulser T, et al. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 2004;45:304-13.
11. Shariat SF, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Ludecke G, et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 2006;176:919-26.
12. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point-ofcare proteomic assay. JAMA 2005;293:810-6.
13. Yoder BJ, Skacel M, Hedgepeth R, Babineau D, Ulchaker JC, Liou LS, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007;127:295-301.
14. Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscleinvasive bladder cancer. Eur Urol 2007;51:1275-80.
15. Gudjonsson S, Isfoss BL, Hansson K, Domanski AM, Warenholt J, Soller W, et al. The value of the UroVysion® assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 2007; e-pub Dec 7. doi:10.1016/j.eururo.2007. 11.051
16. van der Aa MN, Zwarthoff EC, Steyerberg EW, Boogaard MW, Nijsen Y, van der Keur KA, et al. Microsatellite Analysis of Voided-Urine Samples for Surveillence of Low-Grade Non-Muscle-Invasive Urothelial Carcinoma: Feasibility and Clinical Utility in a Prospective Multicenter Study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]). Eur Urol. 2008 May 15.
17. Bartoletti R, Cai T, Dal Canto M, Boddi V, Nesi G, Piazzini M. Multiplex polymerase chain reaction for microsatellite analysis of urine sediment cells: a rapid and inexpensive method for diagnosing and monitoring superficial transitional bladder cell carcinoma. J Urol 2006;175:2032-7.
18. Frigerio S, Padberg BC, Strebel RT, Lenggenhager DM, Messthaler A, Abdou MT, et al. Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis. Int J Cancer 2007;121:329-38.
19. Laird PW. Cancer epigenetics. Hum Mol Genet 2005; 14(Spec No 1):R65-76.
20. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995;55:4531-5.
21. Gonzalgo ML, Datar RH, Schoenberg MP, Cote RJ. The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer. Urol Oncol 2007;25:228-35.
22. Knowles MA. Tumor suppressor loci in bladder cancer. Front Biosci 2007;12:2233-51.
23. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006;98:996-1004.
24. Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, Catto JW. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene 2006;25:1984-8.
25. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955-9.
26. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.
27. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912-21.
28. Rieger-Christ KM, Mourtzinos A, Lee PJ, Zagha RM, Cain J, Silverman M, et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 2003;98:737-44.
29. van Rhijn BW, Smit M, van Geenen D, Wijnmaalen A, Kirkels WJ, van der Kwast TH, et al. Surveillance with microsatellite analysis of urine in bladder cancer patients treated by radiotherapy. Eur Urol 2003;43:369-73.
30. van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005;11:7743-8.
31. Vlahou A, Giannopoulos A, Gregory BW, Manousakas T, Kondylis FI, Wilson LL, et al. Protein profiling in urine for the diagnosis of bladder cancer. Clin Chem 2004;50:1438-41.
32. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491-502.
33. Zhang YF, Wu DL, Guan M, Liu WW, Wu Z, Chen YM, et al. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin Biochem 2004;37:772-9.
34. Liu W, Guan M, Wu D, Zhang Y, Wu Z, Xu M, et al. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur Urol 2005;47:456-62.
35. Mueller J, von Eggeling F, Driesch D, Schubert J, Melle C, Junker K. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur Urol 2005;47:885-93.
36. Munro NP, Cairns DA, Clarke P, Rogers M, Stanley AJ, Barrett JH, et al. Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer 2006;119:2642-50.
37. Lokeshwar VB, Block NL. HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade. Urol Clin North Am 2000;2:53-61.
38. Lokeshwar VB, Obek C, Pham HT, Wei D, Young MJ, Duncan RC, et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 2000;163:348-56.
39. Hautmann S, Toma M, Lorenzo Gomez MF, Friedrich MG, Jaekel T, Michl U, et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol 2004;46:466-71.
40. Lokeshwar VB, Selzer MG, Unwala DJ, Estrella V, Gomez MF, Golshani R, et al. Uronate peaks and urinary hyaluronic acid levels correlate with interstitial cystitis severity. J Urol 2006;176:1001-7.
41. Eissa S, Kassim SK, Labib RA, El-Khouly IM, Ghaffer TM, Sadek M, et al. Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer 2005;103:1356-62.
42. Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, et al. Soluble Fas - a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 2006;106:1701-7.
43. Vriesema JL, Poucki MH, Kiemeney LA, Witjes JA. Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis. Urology 2000;56:793-7.
44. Yossepowitch O, Herr HW, Donat SM. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J Urol 2007;177:1277-82.
45. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 2003;95:588-97.